Turning cold tumors hot: from molecular mechanisms to clinical applications
J Zhang, D Huang, PE Saw, E Song - Trends in immunology, 2022 - cell.com
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
Resistance mechanisms to anti-PD cancer immunotherapy
The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …
[HTML][HTML] Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer
A Fu, B Yao, T Dong, Y Chen, J Yao, Y Liu, H Li, H Bai… - Cell, 2022 - cell.com
Tumor-resident intracellular microbiota is an emerging tumor component that has been
documented for a variety of cancer types with unclear biological functions. Here, we …
documented for a variety of cancer types with unclear biological functions. Here, we …
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs)
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we …
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we …
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Previous studies have suggested that the gut microbiome influences the response to
checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial …
checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial …
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
G Morad, BA Helmink, P Sharma, JA Wargo - Cell, 2021 - cell.com
Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
The microbiome and human cancer
BACKGROUND Historical accounts linking cancer and microbes date as early as four
millennia ago. After establishment of the germ theory of infectious diseases, clinical research …
millennia ago. After establishment of the germ theory of infectious diseases, clinical research …
Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance
S Bagchi, R Yuan, EG Engleman - Annual Review of Pathology …, 2021 - annualreviews.org
Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …